- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CB2 Insights Announces Ticker Symbol Change on OTCQB
CB2 Insights (CSE:CBII) (OTCQB:CBIIF) a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real-World Evidence, today announced that effective immediately, its ticker symbol on the OTCQB Markets has changed from “CBTOF” to the symbol “CBIIF”.
CB2 Insights (CSE:CBII) (OTCQB:CBIIF) a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real-World Evidence, today announced that effective immediately, its ticker symbol on the OTCQB Markets has changed from “CBTOF” to the symbol “CBIIF”. There is no action required by current shareholders in connection with this change.
The Company has also been listed on the Canadian Securities Exchange under the symbol “CBII” since March 6, 2019.
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.
For more information please visit www.cb2insights.com.
Primary Contact
Dan Thompson
1.416.670.9316
dan.thompson@cb2insights.com
For Investor Inquiries
Sophic Capital
1.647.362.8286
investors@cb2insights.com
For Media Inquiries:
KCSA Strategic Communications
cb2@kcsa.com
No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.
Click here to connect with CB2 Insights (CSE:CBII) for an Investor Presentation.
Source: www.globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.